The DOJ's historic move to reclassify marijuana as a Schedule III drug is removing massive tax burdens and sparking immediate optimism across the cannabis sector. This policy shift unlocks new profitability and operational pathways for medical producers, dispensaries, and pharmaceutical researchers navigating the newly regulated landscape.
Published on April 24
The DOJ's decision to reschedule marijuana is the biggest federal cannabis policy change in decades. Moments like this have historically sparked significant moves in the stocks directly affected.
The removal of the IRC Section 280E tax rule means cannabis companies can now claim standard business deductions — something that was previously denied to them. That change alone could transform the profitability of companies in this group.
From pharmaceutical researchers to institutional investors, this reclassification has put cannabis firmly on the radar of serious market participants. Professional analysts curated this basket to capture the companies best positioned to benefit.
The U.S. Department of Justice's decision to move marijuana from Schedule I to Schedule III is one of the most significant regulatory shifts in cannabis history. This change bridges the gap between federal prohibition and state-level medical programmes, and our analysts believe it unlocks a wave of new profitability for companies across the cannabis value chain — from cultivators to pharmaceutical researchers.
This is a high-growth, catalyst-driven theme, meaning it's built around a specific policy event rather than long-term earnings history. The removal of the IRC Section 280E tax burden — which previously prevented cannabis businesses from claiming standard deductions — could dramatically improve cash flows. This group includes individual stocks and ETFs, offering both targeted and diversified exposure.
Every asset in this group was handpicked by professional analysts as a direct or indirect beneficiary of the DOJ rescheduling decision. Whether it's licensed medical producers gaining operational advantages, pharmaceutical researchers facing fewer regulatory hurdles, or sector-tracking ETFs capturing broad market optimism, each pick has a clear and reasoned connection to this historic policy shift.
Total market cap is $.000 and the basket currently has no constituents, so it lacks large-cap anchors. Consequently, there is no inherent market-cap profile to assess.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
+1
Here are a few of the assets in this group. Create an account to unlock the full list.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+256.87%
On average, analysts expect assets in this group to grow 256.87% over the next year.
1 of 10 assets in this group are rated Buy by professional analysts.
